Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ALNY with free AI briefings, catalyst countdowns, and dilution alerts.

ALNY · ALNYLAM PHARMACEUTICALS, INC.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$3.6B Cash on Hand
CF+ Cash Runway
Follow ALNY by email Get an email when ALNY reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ALNY, unsubscribe in one click. Privacy

📣 What ALNY Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Vutrisiran
FDA approved Jun 2022 · Amvuttra
Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy Phase 3 · NCT07223203 Recruiting
Patisiran
FDA approved Aug 2018 · Onpattro
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy Phase 3 · NCT03997383 Completed
Lumasiran
FDA approved Nov 2020 · Oxlumo
Primary Hyperoxaluria Type 1 Phase 3 · NCT04152200 Completed
Givosiran
FDA approved Nov 2019 · Givlaari
Acute Hepatic Porphyria N/A · NCT04056481 Approved for marketing
Zilebesiran High Risk Cardiovascular Disease Phase 3 · NCT07181109 Recruiting
Nucresiran Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy Phase 3 · NCT07223203 Recruiting
Cemdisiran IgA Nephropathy (IgAN) Phase 2 · NCT03841448 Terminated
Elebsiran Chronic Hepatitis B Phase 2 · NCT04412863 Completed
Peginterferon Alfa-2a Chronic Hepatitis B Phase 2 · NCT04412863 Completed
Olmesartan Hypertension Phase 2 · NCT05103332 Completed
Mivelsiran Down Syndrome-Associated Alzheimer's Disease (DS-AD) Phase 2 · NCT07636811 Recruiting
ALN-2232 Obesity Phase 1/2 · NCT07463846 Recruiting
Amlodipine Hypertension Phase 2 · NCT05103332 Completed
ALN-KHK Type 2 Diabetes Mellitus (T2DM) Phase 1/2 · NCT05761301 Terminated
ALN-4324 Obese or Overweight Healthy Volunteers Phase 1/2 · NCT06845202 Active not recruiting
ALN-6400 Hereditary Hemorrhagic Telangiectasia Phase 1/2 · NCT06659640 Active not recruiting

Also used in these trials (approved or third-party drugs, not ALNY's own candidates): Tirzepatide, Indapamide, Pembrolizumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ALNY holds $3.6B in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ALNY files for a raise →

👥 Who Owns ALNY

Insiders 0.2% Institutions (1178 holders) 99.8% Public and other holders 0%
HolderTypeShares% of sharesAs of
Capital World Investors Institution (13G, 5%+) 13,934,539 10.40% 2026-09-30
FMR LLC Institution (13G, 5%+) 12,675,053 9.46% 2026-09-30
Capital Research Global Investors Institution (13G, 5%+) 10,940,905 8.17% 2026-09-30
T. Rowe Price Investment Management, Inc Institution (13G, 5%+) 10,017,904 7.48% 2026-09-30
Vanguard Capital Management Institution (13G, 5%+) 7,104,536 5.30% 2026-03-31
Vanguard Portfolio Management Institution (13G, 5%+) 6,732,082 5.03% 2026-09-30
Yvonne Greenstreet
Chief Executive Officer, Director · +141,171 options
Insider 96,209 0.07% 2026-09-19
Jeffrey V. Poulton
EVP, Chief Financial Officer · +10,480 options
Insider 61,862 0.05% 2026-03-04
Tolga Tanguler
EVP, Chief Commercial Officer · +10,480 options
Insider 34,297 0.03% 2026-03-04
David E I Pyott
Director · +1,441 options
Insider 33,262 0.02% 2026-11-10
Amy W Schulman
Director · +1,802 options
Insider 25,959 0.02% 2026-11-09
Kevin Joseph Fitzgerald
CSO & EVP, Head of Research · +8,105 options
Insider 21,106 0.02% 2026-03-04

Share count 133,937,576 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full ALNY picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ALNY and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.